ACRS
HEALTHCAREAclaris Therapeutics Inc
$4.78+0.03 (+0.63%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ACRS Today?
No stock-specific AI insight has been generated for ACRS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.16$4.89
$4.78
Fundamentals
Market Cap$668M
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume997K
Avg Volume (10D)—
Shares Outstanding139.7M
ACRS News
20 articles- Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical UpdateYahoo Finance·May 7, 2026
- Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue EstimatesYahoo Finance·May 5, 2026
- Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In GrowthYahoo Finance·May 4, 2026
- Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen PlanusMarketbeat·Apr 28, 2026
- Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 InhibitorYahoo Finance·Apr 28, 2026
- Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026Yahoo Finance·Apr 27, 2026
- Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data IncomingMarketbeat·Apr 14, 2026
- Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual ConferenceYahoo Finance·Apr 8, 2026
- Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138Yahoo Finance·Mar 27, 2026
- Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?Yahoo Finance·Mar 26, 2026
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual MeetingYahoo Finance·Mar 20, 2026
- Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic DermatitisYahoo Finance·Mar 18, 2026
- Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink ConferenceMarketbeat·Mar 10, 2026
- Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare ConferenceMarketbeat·Feb 26, 2026
- Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Feb 26, 2026
- Aclaris: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Feb 26, 2026
- Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
Open$4.81
Previous Close$4.75
Day High$4.88
Day Low$4.70
52 Week High$4.89
52 Week Low$1.16
52-Week Range
$1.16$4.89
$4.78
Fundamentals
Market Cap$668M
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume997K
Avg Volume (10D)—
Shares Outstanding139.7M
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—